Boost osimertinib levels using cobicistat to improve value
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding cobicistat can increase and stabilize the effect level of osimertinib while keeping treatment cost-effective. You would take osimertinib 80 mg daily, with blood tests to see how your body processes the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to take osimertinib 80 mg once daily as your standard treatment
- You are 18 years or older and able to sign the informed consent form
- Your overall health/mobility is limited but not too severe (WHO performance status 2 or less)
- You can and agree to have blood drawn for testing (including drug-processing gene testing)
- Your lung cancer is non-squamous, advanced, and has an EGFR mutation
- You must be able to take cobicistat safely (and you may need to review your current medicines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding febuxostat helps the lung cancer drug osimertinib get into the brain better. It is for people with EGFR-mutated NSCLC who are already taking osimertinib, regardless of whether their cancer is stable or slowly progressing.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.